Global Cell Therapy Market by Therapy Type (Autologous, Allogenic) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global cell therapy market was valued at USD 7.8 Billion in 2020. It is projected to grow at a compound annual rate (CAGR of 14.5%) between 2021 and 2028. The increasing number of clinical trials for cell-based therapies is driving the market. Global investment has been made in clinical research and translation. The presence of private and government funding agencies, which offer grants for projects at all stages of clinical trial development, has led to an increase in ongoing clinical trials.
Additionally, the field of regenerative medicine continues to see significant advances, which will further help with chronic conditions. Many companies are attempting to tap into the potential market for cell therapy in emerging markets like Canada. RepliCel, for example, is investing in several projects in regenerative medicine. In February 2021, RepliCel announced plans to commercialize and test 3 more technologies in Japan. They include two cell-based therapies, one for skin regeneration and the other for tendon renewal.
Market growth has also been aided by the gradual emergence and support of advanced therapies. In order to produce a strong portfolio of candidates, a product must be able to be used as a basis for the introduction of cell lines that are proprietary. Immunicum uses Chimeric Antigen Receptor (CAR) T cell (CAR–T) expansion, dendritic cells neoantigen technology, and primers for T-cells in order to expand their product line in immuno-oncology.
Direct cell reprogramming is a promising therapeutic option that has attracted significant attention. It is more effective and safer. Fortuna Fix, a privately owned company, is preparing to be the first to use clinically available neural stem cells for patients. These will be generated by direct reprogramming to replace neuronal tissue that has been lost in neurodegeneration and neurotrauma. These ongoing activities will be a boost to revenue generation in future.
The market for cell therapy has suffered some losses as a result of the COVID-19 epidemic. The slowing of research progress is a problem. Universities around the world have slowed down enrollment for clinical trials and all other research activities. However, the market is growing with companies such as Novartis offering access to their therapies. MultiStem, a therapy that Athersys, Inc. considers a very relevant option for COVID-19, is also available.
Use-type insights
Research-use was the dominant segment in the cell therapy market and held the largest share of revenue at 60.9% in 2020. Research projects are the main use of stem cells, which has resulted in a high revenue share for this segment. This region will continue to dominate the market from 2021 to 2030. Cell-based therapies have great potential to replace, repair, restore, or regenerate damaged tissues, cells, organs, and cells. As an alternative to traditional treatment methods, researchers are investing heavily in developing safe and effective treatments.
Mesenchymal Stem Cells, also known as MSCs, have many clinical applications. They can help to moderate the immune system. In 2020, MSC-based therapy has been a hot topic among professionals. This can be attributed to the fact that MSCs lack Angiotensin-converting Enzyme-2 (ACE2) receptor. Coronaviruses require this receptor to enter host cells. It has a large distribution on the human cell surface. MSCs can be injected into host cells without any coronavirus interference.
Due to the lower penetration of this segment, the clinical-use segment will grow slowly at 13.4% over the forecast period. CARTISTEM and Invossa are not approved cell therapies for clinical applications. This is expected to encourage companies to invest in the segment.
Therapy Type Insights
Autologous therapies dominated the cell therapy market, accounting for 53.2% of the total revenue in 2020. This segment is expected to continue its dominance over the forecast period. Autologous transplants offer several benefits, including easy availability, the lack of need to find a HLA-matched donor, lower risks of life-threatening complications, and no need for immunosuppressive therapy. Segment growth can also make autologous therapies more affordable than allogenic therapies.
Due to the high cost of allogenic transplants, and lower relapse rates, the allogenic therapies market is expected to experience a slow growth rate from 2021 to 2028. The cell therapy market is being driven by the growth of cell banking and the shift in companies towards developing allogenic therapy products.
Regional Insights
North America will hold 52.7% of the global market in 2020, according to estimates. A large number of institutes and centers that conduct stem cell therapy research in the region is responsible for the high market share. Five of the 8 such leading universities in the world are U.S.-based, including Institute for Stem Cell Biology and Regenerative Medicine at Stanford University, Harvard Stem Cell Institute and Harvard University and Yale Stem Cell Center.
The Asia Pacific market for cell therapy will experience a 15.52% growth rate over the forecast period. This region's developing economies will see a rise in investment from both consumers and developers to educate themselves for advanced medical therapies. Many stem cell associations exist in Asian countries. They aim to ensure coordinated and targeted R&D programs. Due to the flexibility of the legal framework, it is not uncommon for patients from Western countries to migrate to Asia to receive treatment.
Market Share Insights & Key Companies
U.S. FDA approvals are being granted to companies for stem cell therapy. In September 2020, FDA approved Stemedica Cell Technologies, Inc. with Investigational New Drug approval. This was to allow them to conduct phase II trials of intravenously administered allogeneic MSCs for covid-19 patients. These MSCs are an attractive new biological therapy for COVID-19 because of their immunomodulatory properties, low immunogenicity and ability to suppress excessive pro-inflammatory reactions. The cell therapy market is dominated by:
-
Kolon TissueGene, Inc.
-
Anterogen Co., Ltd.
-
JCR Pharmaceuticals Co., Ltd.
-
Castle Creek Biosciences, Inc.
-
The Future of Biotechnology, Medipost
-
Osiris Therapeutics, Inc.
-
PHARMICELL Company, Ltd
-
Tameika Cell Technologies, Inc.
-
Cells for cells
-
NuVasive, Inc.
-
Vericel Corporation
-
Celgene Corporation
Up Market Research published a new report titled “Cell Therapy Market research report which is segmented by Therapy Type (Autologous, Allogenic), By Players/Companies Tameika Cell Technologies Inc, Cells for Cells, Anterogen Co Ltd, The Future of Biotechnology MEDIPOST, NuVasive Inc, PHARMICELL Co Ltd, JCR Pharmaceuticals Co Ltd , Castle Creek Biosciences Inc, Vericel Corporation, Kolon TissueGene Inc, Celgene Corporation, Osiris Therapeutics Inc”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Cell Therapy Market Research Report |
| By Therapy Type | Autologous, Allogenic |
| By Companies | Tameika Cell Technologies Inc, Cells for Cells, Anterogen Co Ltd, The Future of Biotechnology MEDIPOST, NuVasive Inc, PHARMICELL Co Ltd, JCR Pharmaceuticals Co Ltd , Castle Creek Biosciences Inc, Vericel Corporation, Kolon TissueGene Inc, Celgene Corporation, Osiris Therapeutics Inc |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 240 |
| Number of Tables & Figures | 168 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Cell Therapy Market Report Segments:
The market is segmented by Therapy Type (Autologous, Allogenic).
Cell Therapy Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Cell Therapy Market
Overview of the regional outlook of the Cell Therapy Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Cell Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Cell Therapy Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Autologous
2. Allogenic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cell Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Cell Therapy Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cell Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cell Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cell Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cell Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cell Therapy Market Size & Forecast, 2018-2028
4.5.1 Cell Therapy Market Size and Y-o-Y Growth
4.5.2 Cell Therapy Market Absolute $ Opportunity
Chapter 5 Global Cell Therapy Market Analysis and Forecast by Therapy Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Therapy Type
5.1.2 Basis Point Share (BPS) Analysis by Therapy Type
5.1.3 Absolute $ Opportunity Assessment by Therapy Type
5.2 Cell Therapy Market Size Forecast by Therapy Type
5.2.1 Autologous
5.2.2 Allogenic
5.3 Market Attractiveness Analysis by Therapy Type
Chapter 6 Global Cell Therapy Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Cell Therapy Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Cell Therapy Analysis and Forecast
8.1 Introduction
8.2 North America Cell Therapy Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Cell Therapy Market Size Forecast by Therapy Type
8.6.1 Autologous
8.6.2 Allogenic
8.7 Basis Point Share (BPS) Analysis by Therapy Type
8.8 Absolute $ Opportunity Assessment by Therapy Type
8.9 Market Attractiveness Analysis by Therapy Type
Chapter 9 Europe Cell Therapy Analysis and Forecast
9.1 Introduction
9.2 Europe Cell Therapy Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Cell Therapy Market Size Forecast by Therapy Type
9.6.1 Autologous
9.6.2 Allogenic
9.7 Basis Point Share (BPS) Analysis by Therapy Type
9.8 Absolute $ Opportunity Assessment by Therapy Type
9.9 Market Attractiveness Analysis by Therapy Type
Chapter 10 Asia Pacific Cell Therapy Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Cell Therapy Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Cell Therapy Market Size Forecast by Therapy Type
10.6.1 Autologous
10.6.2 Allogenic
10.7 Basis Point Share (BPS) Analysis by Therapy Type
10.8 Absolute $ Opportunity Assessment by Therapy Type
10.9 Market Attractiveness Analysis by Therapy Type
Chapter 11 Latin America Cell Therapy Analysis and Forecast
11.1 Introduction
11.2 Latin America Cell Therapy Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Cell Therapy Market Size Forecast by Therapy Type
11.6.1 Autologous
11.6.2 Allogenic
11.7 Basis Point Share (BPS) Analysis by Therapy Type
11.8 Absolute $ Opportunity Assessment by Therapy Type
11.9 Market Attractiveness Analysis by Therapy Type
Chapter 12 Middle East & Africa (MEA) Cell Therapy Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Cell Therapy Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Cell Therapy Market Size Forecast by Therapy Type
12.6.1 Autologous
12.6.2 Allogenic
12.7 Basis Point Share (BPS) Analysis by Therapy Type
12.8 Absolute $ Opportunity Assessment by Therapy Type
12.9 Market Attractiveness Analysis by Therapy Type
Chapter 13 Competition Landscape
13.1 Cell Therapy Market: Competitive Dashboard
13.2 Global Cell Therapy Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 Tameika Cell Technologies Inc
13.3.2 Cells for Cells
13.3.3 Anterogen Co Ltd
13.3.4 The Future of Biotechnology MEDIPOST
13.3.5 NuVasive Inc
13.3.6 PHARMICELL Co Ltd
13.3.7 JCR Pharmaceuticals Co LtdÂ
13.3.8 Castle Creek Biosciences Inc
13.3.9 Vericel Corporation
13.3.10 Kolon TissueGene Inc
13.3.11 Celgene Corporation
13.3.12 Osiris Therapeutics Inc
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cell Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cell Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cell Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cell Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cell Therapy Market Size & Forecast, 2018-2028
4.5.1 Cell Therapy Market Size and Y-o-Y Growth
4.5.2 Cell Therapy Market Absolute $ Opportunity
Chapter 5 Global Cell Therapy Market Analysis and Forecast by Therapy Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Therapy Type
5.1.2 Basis Point Share (BPS) Analysis by Therapy Type
5.1.3 Absolute $ Opportunity Assessment by Therapy Type
5.2 Cell Therapy Market Size Forecast by Therapy Type
5.2.1 Autologous
5.2.2 Allogenic
5.3 Market Attractiveness Analysis by Therapy Type
Chapter 6 Global Cell Therapy Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Cell Therapy Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Cell Therapy Analysis and Forecast
8.1 Introduction
8.2 North America Cell Therapy Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Cell Therapy Market Size Forecast by Therapy Type
8.6.1 Autologous
8.6.2 Allogenic
8.7 Basis Point Share (BPS) Analysis by Therapy Type
8.8 Absolute $ Opportunity Assessment by Therapy Type
8.9 Market Attractiveness Analysis by Therapy Type
Chapter 9 Europe Cell Therapy Analysis and Forecast
9.1 Introduction
9.2 Europe Cell Therapy Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Cell Therapy Market Size Forecast by Therapy Type
9.6.1 Autologous
9.6.2 Allogenic
9.7 Basis Point Share (BPS) Analysis by Therapy Type
9.8 Absolute $ Opportunity Assessment by Therapy Type
9.9 Market Attractiveness Analysis by Therapy Type
Chapter 10 Asia Pacific Cell Therapy Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Cell Therapy Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Cell Therapy Market Size Forecast by Therapy Type
10.6.1 Autologous
10.6.2 Allogenic
10.7 Basis Point Share (BPS) Analysis by Therapy Type
10.8 Absolute $ Opportunity Assessment by Therapy Type
10.9 Market Attractiveness Analysis by Therapy Type
Chapter 11 Latin America Cell Therapy Analysis and Forecast
11.1 Introduction
11.2 Latin America Cell Therapy Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Cell Therapy Market Size Forecast by Therapy Type
11.6.1 Autologous
11.6.2 Allogenic
11.7 Basis Point Share (BPS) Analysis by Therapy Type
11.8 Absolute $ Opportunity Assessment by Therapy Type
11.9 Market Attractiveness Analysis by Therapy Type
Chapter 12 Middle East & Africa (MEA) Cell Therapy Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Cell Therapy Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Cell Therapy Market Size Forecast by Therapy Type
12.6.1 Autologous
12.6.2 Allogenic
12.7 Basis Point Share (BPS) Analysis by Therapy Type
12.8 Absolute $ Opportunity Assessment by Therapy Type
12.9 Market Attractiveness Analysis by Therapy Type
Chapter 13 Competition Landscape
13.1 Cell Therapy Market: Competitive Dashboard
13.2 Global Cell Therapy Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 Tameika Cell Technologies Inc
13.3.2 Cells for Cells
13.3.3 Anterogen Co Ltd
13.3.4 The Future of Biotechnology MEDIPOST
13.3.5 NuVasive Inc
13.3.6 PHARMICELL Co Ltd
13.3.7 JCR Pharmaceuticals Co LtdÂ
13.3.8 Castle Creek Biosciences Inc
13.3.9 Vericel Corporation
13.3.10 Kolon TissueGene Inc
13.3.11 Celgene Corporation
13.3.12 Osiris Therapeutics Inc
Segments Covered in the Report
The global Cell Therapy market has been segmented based on
By Therapy Type
The global Cell Therapy market has been segmented based on
By Therapy Type
- Autologous
- Allogenic
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Tameika Cell Technologies Inc
- Cells for Cells
- Anterogen Co Ltd
- The Future of Biotechnology MEDIPOST
- NuVasive Inc
- PHARMICELL Co Ltd
- JCR Pharmaceuticals Co LtdÂ
- Castle Creek Biosciences Inc
- Vericel Corporation
- Kolon TissueGene Inc
- Celgene Corporation
- Osiris Therapeutics Inc
Our Clients
Related Reports
Some other reports from this category!
